Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137069 · ClinicalTrials.gov registry record · Phase 2
A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
A Phase 2 study of Urticaria, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
- 20
- Study locations
NCT03137069 is a Phase 2 study of Urticaria that has completed, run by Genentech. The registered enrollment target is 134 participants, above the 16-participant average among 3 other Urticaria trials with a reported enrollment target (738% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT03137069, a Phase 2 study of Urticaria, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of GDC-0853 compared with placebo in participants with Refractory Chronic Spontaneous Urticaria (CSU) already treated with anti-histamines. Participants have the option to enter the Open-Label Extension (OLE) study after completing the 8-week treatment period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GDC-0853
Study Locations (20)
California
- Kern Allergy Med Clinic, Inc. - Bakersfield
- Southern California Research Center - Mission Viejo
- Allergy & Asthma Consultants - Redwood City
- Integrated Research Group Inc - Riverside
- Integrated Research of Inland - Upland
Ontario
- Private Practice - Dr. Jason Ohayon - Hamilton
- Lynde Institute for Dermatology - Markham
- Cheema Research - Mississauga
- Yang Medicine - Ottawa
- Gordon Sussman Clinical Research - Toronto
Florida
- New Horizon Research Center - Miami
- Renstar Medical Research - Ocala
Alabama
- Clinical Research Center of Alabama, LLC - Birmingham
Arizona
- Allergy & Asthma Immunology Associates - Scottsdale
Oklahoma
- Vital Prospects Clinical Research Institute PC - CRN - Tulsa
Rhode Island
- Asthma, Nasal Disease, and Allergy Research Center of New England - East Providence
Texas
- Center for Clinical Studies - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2017-05-26 |
| Est. Completion | 2019-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03137069
The ClinicalTrials.gov registry entry for NCT03137069 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 16-participant average among 3 other Urticaria trials with a reported enrollment target (738% higher). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urticaria appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03137069 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Ontario, Florida.
Frequently Asked Questions
What is clinical trial NCT03137069 about?
NCT03137069 is a clinical study titled "A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).". The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of GDC-0853 compared with placebo in participants with Refractory Chronic Spontaneous Urticaria (CSU) already treated with anti-histamines. Participants have the option to enter the Open-Label Extension (OLE) study af...
What is the current status of trial NCT03137069?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2017-05-26. Estimated completion is 2019-10-25.
What conditions does trial NCT03137069 study?
This clinical trial studies the following conditions: Urticaria.
What interventions are being tested in trial NCT03137069?
The interventions under investigation include: Placebo (DRUG), GDC-0853 (DRUG).
Who is sponsoring clinical trial NCT03137069?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03137069 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.